82 FR 18307 - Agency Information Collection Activities: Proposed Collection; Comment Request
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration Federal Register Volume 82, Issue 73 (April 18, 2017)
Substance Abuse and Mental Health Services Administration
Federal Register Volume 82, Issue 73 (April 18, 2017)
| Page Range | 18307-18308 | |
| FR Document | 2017-07764 |
[Federal Register Volume 82, Number 73 (Tuesday, April 18, 2017)] [Notices] [Pages 18307-18308] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-07764] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVCES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Proposed Collection; Comment Request In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed project or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer at (240) 276-1243. Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: Strategic Prevention Framework for Prescription Drugs (SPF-Rx)--New The Substance Abuse and Mental Health Services Administration (SAMHSA)'s Center for Substance Abuse Prevention (CSAP) aims to conduct a cross-site evaluation of the Strategic Prevention Framework for Prescription Drugs (SPF-Rx) program. The SPF-Rx program is designed to address nonmedical use of prescription drugs (as well as opioid overdoses) by raising awareness about the dangers of sharing medications. and by working with pharmaceutical and medical communities. The SPF-Rx program aims to promote collaboration between states/tribes and pharmaceutical and medical communities to understand the risks of overprescribing to youth ages 12-17 and adults 18 years of age and older. The program also aims to enhance capacity for, and access to, Prescription Drug Monitoring Program (PDMP) data for prevention purposes. The SPF-Rx program aims to address SAMHSA's priorities on prevention and [[Page 18308]] reduction of prescription drug and illicit opioid misuse and abuse. Its indicators of success are reductions in opioid overdoses and the incorporation of PDMP data into needs assessments and strategic plans. Data collected through the tools described in this statement will be used for the national cross-site evaluation of SAMHSA's SPF-Rx program. This package covers continued data collection through 2020, as the evaluation is expected to continue through at least that time; however, the Program Evaluation for Prevention Contract (PEP-C) is scheduled to conduct a national cross-site evaluation of SPF-Rx through September 2018. The PEP-C team will systematically collect and maintain an Annual Implementation Instrument (AII) and outcomes data submitted by SPF-Rx grantees through the online PEP-C Management Reporting Tool (MRT). SAMHSA is requesting approval for data collection for the SPF-Rx cross-site evaluation with the following four instruments:Grantee Interview to obtain the perspective of the implementing Project Directors (PDs) or their staff on important topics, including infrastructure and capacity, collaboration, leveraging funding and resources, criteria and use of evidence-informed interventions, monitoring and evaluation, collaboration, challenges, and health disparities. Information from these interviews will help inform SPF-Rx cross-site evaluation reports and will help identify lessons learned and success stories from grantees' SPF-Rx programs. Grantee- and Community-Level Outcomes Modules to collect data on key SPF-Rx program outcomes, including opioid misuse and abuse, opioid overdoses, and opioid prescribing patterns. Grantees will provide outcomes data at the grantee level for their state, tribal area, or jurisdiction, as well as at the community level for each of their subrecipient communities. Substitute Data Source Request to allow grantees to request permission from SAMHSA to use ``substitute measures'' for their outcomes data--that is, measures that differ from a list of preapproved outcomes measures. Annual Implementation Instrument to collect data completed by grantees and subrecipient community PDs. Data collected from the survey will be used to monitor subrecipient and state, tribal entity, or jurisdiction performance, and to evaluate the effectiveness of the SPF-Rx program across states, tribal entities, and jurisdictions. Grantee Interview to collect semistructured telephone interview data to gather more in-depth information on organizational infrastructure, use of PDMP data. Evaluation Plan to allow grantees to outline their local evaluation plan. This section should include goals and objectives, performance measures, a data analysis plan, and reporting plan. Annualized Data Collection Burden ---------------------------------------------------------------------------------------------------------------- Number of Responses per Total number Hours per Total burden Instrument respondents respondent of responses response hours ---------------------------------------------------------------------------------------------------------------- Grantee-Level Outcomes Module... 25 1 25 3 75 Community-Level Outcomes Module. 25 1 25 3 75 Substitute Data Request Form.... 3.67 1 3.67 1 3.67 Annual Implementation Instrument 100 1 100 2.3 230 Grantee-Level Interview......... 17 1 17 1.5 25.5 Evaluation Plan................. 25 1 25 8 200 Overall Total............... 170.67 .............. 170.67 .............. 609.17 ---------------------------------------------------------------------------------------------------------------- Note: Annualized Data Collection Burden captures the average number of respondents and responses, burden hours, and respondent cost over the 3 years (FY2018-FY2020). Send comments to Summer King, SAMHSA Reports Clearance Officer, 5600 Fishers Lane, Room 15E57-B, Rockville, Maryland 20857, OR email a copy to [email protected]. Written comments should be received by June 19, 2017. Summer King, Statistician. [FR Doc. 2017-07764 Filed 4-17-17; 8:45 am] BILLING CODE 4162-20-P
![Federal Register / Vol. 82, No. 73 / Tuesday, April 18, 2017 / Notices 18307
Translational Sciences (NCATS) and the 2. Information Requested DEPARTMENT OF HEALTH AND
National Institute of Diabetes and HUMAN SERVCES
Digestive and Kidney Diseases (NIDDK). NIH is seeking input from national
and international experts and interested Substance Abuse and Mental Health
ADDRESSES: Submissions may be sent members of the public that includes, but Services Administration
electronically to DK-IDG-Phase2-RFI@ is not limited to, the following areas:
mail.nih.gov or by mail to Dr. Karlie Agency Information Collection
Sharma, National Center for Advancing • Resources that an outside
Activities: Proposed Collection;
Translational Sciences, National organization (biotechnology or
Comment Request
Institutes of Health, 6701 Democracy pharmaceutical company; non-profit
Blvd., Suite 900, Bethesda, MD 20892. organization; academic institution and In compliance with Section
national/international consortia) might 3506(c)(2)(A) of the Paperwork
FOR FURTHER INFORMATION CONTACT:
be willing to share with the IDG Reduction Act of 1995 concerning
Questions about this request for opportunity for public comment on
Program and may:
information should be directed to Dr. proposed collections of information, the
Karlie Sharma, National Center for Æ Strategize development of chemical
Substance Abuse and Mental Health
Advancing Translational Sciences, probes against proteins drawn from
Services Administration (SAMHSA)
National Institutes of Health, 6701 the IDG focused list
will publish periodic summaries of
Democracy Blvd., Suite 900, Bethesda, Æ develop assays and platforms that can proposed projects. To request more
MD 20892, DK-IDG-Phase2-RFI@ help to answer questions about information on the proposed project or
mail.nih.gov, 301–451–4965. understudied protein function to obtain a copy of the information
SUPPLEMENTARY INFORMATION: Out of the Æ identify reagents that may be useful collection plans, call the SAMHSA
nearly 30,000 genes in the human in annotation efforts Reports Clearance Officer at (240) 276–
genome, approximately 3,000 genes are 1243.
Æ provide data or knowledge on any Comments are invited on: (a) Whether
estimated to be part of the druggable
genome—the subset of genes expressing understudied protein the proposed collection of information
proteins with the ability to bind drug- • Potential resources of the IDG is necessary for the proper performance
like molecules. Yet, only about ten Program that are of interest to an outside of the functions of the agency, including
percent of druggable proteins are organization of the broader biomedical whether the information shall have
targeted by Food and Drug research community including: practical utility; (b) the accuracy of the
Administration (FDA)-approved drugs. Æ Sharable databases of relevant subsets agency’s estimate of the burden of the
Many proteins that comprise the of data on understudied proteins proposed collection of information; (c)
druggable genome are members of the G- ways to enhance the quality, utility, and
protein coupled receptor (GPCR), ion Æ data analysis and query tools clarity of the information to be
channel, and kinase families. A Æ links between protein target and collected; and (d) ways to minimize the
significant number of proteins within disease pathologies burden of the collection of information
these classes are understudied and are Æ new methods of analysis to accelerate on respondents, including through the
the focus of the data and resource use of automated collection techniques
collection of data
generation initiative of the IDG Program. or other forms of information
This RFI is for planning purposes technology.
1. Goals and Requirements only and should not be construed as a
solicitation for applications or Proposed Project: Strategic Prevention
The IDG Program was originally Framework for Prescription Drugs
funded as a three-year pilot program in proposals, or as an obligation in any
(SPF-Rx)—New
2014 with two overarching goals: (1) way on the part of the United States
Integrate information about Federal government. The Federal The Substance Abuse and Mental
understudied druggable proteins from government will not pay for the Health Services Administration
disparate sources into a single preparation of any information (SAMHSA)’s Center for Substance
informatics site and (2) foster submitted or for the government’s use. Abuse Prevention (CSAP) aims to
technology development to enable the Additionally, the government cannot conduct a cross-site evaluation of the
determination of function and guarantee the confidentiality of the Strategic Prevention Framework for
therapeutic potential of understudied information provided. Prescription Drugs (SPF-Rx) program.
druggable proteins. Having successfully The SPF-Rx program is designed to
Dated: April 12, 2017. address nonmedical use of prescription
achieved these goals, the IDG Program is
currently transitioning to a new Christopher P. Austin, drugs (as well as opioid overdoses) by
implementation phase intended to: Director, NCATS. raising awareness about the dangers of
sharing medications. and by working
• Expand the informatics tools Griffin P. Rodgers,
Director, NIDDK, Illuminating the Druggable
with pharmaceutical and medical
developed in the pilot phase to include
Genome Program, National Center for communities. The SPF-Rx program aims
additional data and allow users to
Advancing Translational Sciences, National to promote collaboration between states/
access, analyze, and visualize a wide
Institute of Diabetes and Digestive and Kidney tribes and pharmaceutical and medical
range of information on sets of proteins.
Diseases. communities to understand the risks of
• Facilitate the elucidation of the overprescribing to youth ages 12–17 and
sradovich on DSK3GMQ082PROD with NOTICES
[FR Doc. 2017–07795 Filed 4–17–17; 8:45 am]
function of understudied proteins from adults 18 years of age and older. The
the three key druggable protein families BILLING CODE 4140–01–P
program also aims to enhance capacity
(GPCR, ion channels, and kinases) by for, and access to, Prescription Drug
generating new reagents and new data. Monitoring Program (PDMP) data for
• Disseminate the IDG-generated prevention purposes.
resources and data to the greater The SPF-Rx program aims to address
scientific community. SAMHSA’s priorities on prevention and
VerDate Sep<11>2014 16:55 Apr 17, 2017 Jkt 241001 PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 E:\FR\FM\18APN1.SGM 18APN1](https://thefederalregister.org/doc/82_FR_18380/page/1.svg)
![18308 Federal Register / Vol. 82, No. 73 / Tuesday, April 18, 2017 / Notices
reduction of prescription drug and illicit • Grantee Interview to obtain the • Substitute Data Source Request to
opioid misuse and abuse. Its indicators perspective of the implementing Project allow grantees to request permission
of success are reductions in opioid Directors (PDs) or their staff on from SAMHSA to use ‘‘substitute
overdoses and the incorporation of important topics, including measures’’ for their outcomes data—that
PDMP data into needs assessments and infrastructure and capacity, is, measures that differ from a list of
strategic plans. Data collected through collaboration, leveraging funding and preapproved outcomes measures.
the tools described in this statement resources, criteria and use of evidence-
will be used for the national cross-site • Annual Implementation Instrument
informed interventions, monitoring and to collect data completed by grantees
evaluation of SAMHSA’s SPF-Rx evaluation, collaboration, challenges,
program. This package covers continued and subrecipient community PDs. Data
and health disparities. Information from
data collection through 2020, as the collected from the survey will be used
these interviews will help inform SPF-
evaluation is expected to continue to monitor subrecipient and state, tribal
Rx cross-site evaluation reports and will
through at least that time; however, the entity, or jurisdiction performance, and
help identify lessons learned and
Program Evaluation for Prevention to evaluate the effectiveness of the SPF-
success stories from grantees’ SPF-Rx
Contract (PEP–C) is scheduled to Rx program across states, tribal entities,
programs.
conduct a national cross-site evaluation and jurisdictions.
of SPF-Rx through September 2018. The • Grantee- and Community-Level
• Grantee Interview to collect
PEP–C team will systematically collect Outcomes Modules to collect data on
key SPF-Rx program outcomes, semistructured telephone interview data
and maintain an Annual to gather more in-depth information on
Implementation Instrument (AII) and including opioid misuse and abuse,
opioid overdoses, and opioid organizational infrastructure, use of
outcomes data submitted by SPF-Rx
prescribing patterns. Grantees will PDMP data.
grantees through the online PEP–C
Management Reporting Tool (MRT). provide outcomes data at the grantee • Evaluation Plan to allow grantees to
SAMHSA is requesting approval for level for their state, tribal area, or outline their local evaluation plan. This
data collection for the SPF-Rx cross-site jurisdiction, as well as at the section should include goals and
evaluation with the following four community level for each of their objectives, performance measures, a
instruments: subrecipient communities. data analysis plan, and reporting plan.
ANNUALIZED DATA COLLECTION BURDEN
Responses
Number of Total number Hours per Total burden
Instrument per
respondents of responses response hours
respondent
Grantee-Level Outcomes Module ........................................ 25 1 25 3 75
Community-Level Outcomes Module ................................... 25 1 25 3 75
Substitute Data Request Form ............................................ 3.67 1 3.67 1 3.67
Annual Implementation Instrument ...................................... 100 1 100 2.3 230
Grantee-Level Interview ....................................................... 17 1 17 1.5 25.5
Evaluation Plan .................................................................... 25 1 25 8 200
Overall Total ................................................................. 170.67 ........................ 170.67 ........................ 609.17
Note: Annualized Data Collection Burden captures the average number of respondents and responses, burden hours, and respondent cost
over the 3 years (FY2018–FY2020).
Send comments to Summer King, DEPARTMENT OF THE INTERIOR a.m. to 4 p.m. The meeting is open to
SAMHSA Reports Clearance Officer, the public. Public comments will be
5600 Fishers Lane, Room 15E57–B, Bureau of Land Management accepted at 11 a.m. to noon.
Rockville, Maryland 20857, OR email a [LLCAN01000 L10200000.XZ0000 17X ADDRESSES: The meeting will be held in
copy to summer.king@samhsa.hhs.gov. LXSIOVHD0000] the conference room of the Bureau of
Written comments should be received Land Management Northern California
by June 19, 2017. Notice of Public Meeting: Northern District Office, 6640 Lockheed Drive,
California District Resource Advisory Redding, CA 96002. Those unable to
Summer King, Council attend can participate by teleconference.
Statistician. The toll-free telephone number is (888)
[FR Doc. 2017–07764 Filed 4–17–17; 8:45 am]
AGENCY: Bureau of Land Management, 282–0374, and the passcode is 50716.
Interior. Written comments can be sent to the
BILLING CODE 4162–20–P
ACTION: Notice. district office at the above address.
FOR FURTHER INFORMATION CONTACT:
SUMMARY: In accordance with the
BLM Northern California District
Federal Land Policy and Management
Manager, Alan Bittner, (530) 224–2160;
Act of 1976, and the Federal Advisory
or Public Affairs Officer, Joseph J.
Committee Act of 1972, the U.S.
sradovich on DSK3GMQ082PROD with NOTICES
Fontana, (530) 252–5332. Persons who
Department of the Interior, Bureau of
use a telecommunications device for the
Land Management’s (BLM) Northern deaf may call the Federal Relay Service
California District Resource Advisory at 800–877–8339, to contact the above
Council (RAC) will meet as indicated individuals during normal business
below. hours. The Service is available 24 hours
The meeting will be held on
DATES: a day, 7 days a week, to leave a message
Wednesday, April 26, 2017, from 10 or question with the above individual.
VerDate Sep<11>2014 16:55 Apr 17, 2017 Jkt 241001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 E:\FR\FM\18APN1.SGM 18APN1](https://thefederalregister.org/doc/82_FR_18380/page/2.svg)
Document Created: 2017-04-18 00:00:18
Document Modified: 2017-04-18 00:00:18
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| FR Citation | 82 FR 18307 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR